Asian Clinical Oncology Group

Asian Clinical Oncology Group
Name	Asian Clinical Oncology Group
Formation	1990s
Type	Research network
Headquarters	Asia
Region served	Asia-Pacific
Membership	Multiple institutions
Leader title	Chair

Asian Clinical Oncology Group is a multinational clinical research consortium focused on oncology clinical trials and translational research across Asia. The consortium convenes academic hospitals, cancer centers, regulatory agencies, pharmaceutical companies, and patient advocacy organizations to harmonize trial design, biomarker studies, and practice guidelines. It engages with regional bodies and global partners to accelerate evidence generation for therapeutics, diagnostics, and health policy adoption across diverse populations.

History

The consortium traces origins to collaborative meetings among institutions such as National Cancer Center Hospital (Japan), Fudan University Shanghai Cancer Center, Chinese Academy of Medical Sciences, Samsung Medical Center, and National University Hospital (Singapore) convened after the 1990s rise in multinational oncology trials. Early initiatives built on frameworks from organizations like World Health Organization, International Agency for Research on Cancer, UICC, and ASCO and responded to differences highlighted by regulators such as Pharmaceuticals and Medical Devices Agency (Japan), China Food and Drug Administration, and Health Sciences Authority (Singapore). Milestones include joint protocols developed after meetings hosted in cities including Tokyo, Shanghai, Seoul, Singapore, and Hong Kong. The group expanded through partnerships with networks such as European Organization for Research and Treatment of Cancer, National Cancer Institute (United States), Translational Research, and regional academic societies like Japanese Society of Medical Oncology, Korean Cancer Association, and Chinese Society of Clinical Oncology.

Mission and Objectives

The consortium aims to address unmet needs reflected in trends documented by GLOBOCAN, International Agency for Research on Cancer, and regional cancer registries in countries including India, Indonesia, Philippines, Thailand, and Malaysia. Objectives include harmonizing trial standards aligned with guidance from ICH and Good Clinical Practice, enabling population-specific pharmacogenomics studies referencing HLA variants and biomarkers identified by centers such as National Cancer Center (Singapore), and accelerating access pathways through engagement with regulatory authorities like Ministry of Health (Thailand) and Ministry of Health and Family Welfare (India). The group emphasizes capacity building with institutions such as Prince of Wales Hospital (Hong Kong), Queen Mary Hospital (Hong Kong), Siriraj Hospital, and AIIMS.

Organizational Structure

Governance commonly features an executive committee with representatives from major institutions including Seoul National University Hospital, King Faisal Specialist Hospital and Research Centre, Christian Medical College, Vellore, and National Taiwan University Hospital. Scientific oversight is provided by steering committees modeled on structures from NCI cooperative groups and includes subcommittees for protocol development, biostatistics often linked to London School of Hygiene & Tropical Medicine collaborations, and bioinformatics partnerships with institutions like Broad Institute and Genome Institute of Singapore. Operational support often draws on clinical trial units such as Cancer Institute (WIA), contract research organizations including Parexel and ICON plc, and ethics review coordination with bodies like Institutional Review Board networks and hospital ethics committees at Rigshospitalet-affiliated centers.

Research Programs and Clinical Trials

Research spans oncology domains historically emphasized at centers such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and regional hubs: gastrointestinal trials involving institutions like Fujian Cancer Hospital, hepatocellular carcinoma studies with National Cancer Center (Korea), lung cancer protocols aligning with efforts from Chinese PLA General Hospital, and breast cancer programs linked to Siriraj Hospital and Tata Memorial Hospital. Trials incorporate molecular stratification using assays developed in collaboration with Wellcome Trust Sanger Institute, Roche, Novartis, Pfizer, AstraZeneca, and diagnostics firms such as Qiagen and Abbott Laboratories. The consortium runs investigator-initiated trials, phase I/II translational studies, and registration trials designed for submissions to agencies like PMDA and European Medicines Agency, and collaborates on real-world evidence projects drawing from registries like SEER analogues in Asia.

Member Institutions and Collaborations

Membership typically includes academic centers such as Peking University Cancer Hospital, Zhejiang Cancer Hospital, National Cancer Center Hospital East, Kawasaki Medical School, University of Malaya Medical Centre, Monash Medical Centre, and specialty centers including Yonsei Cancer Center and Asan Medical Center. Collaborations extend to pharmaceutical sponsors Bristol-Myers Squibb, Eli Lilly and Company, and biotechnology firms, along with philanthropic funders like Bill & Melinda Gates Foundation and international funders such as Wellcome Trust. The consortium partners with regional societies including Asian Pacific Society of Respirology and Asia-Pacific Society of Medical Oncology to align education and guideline dissemination.

Funding and Governance

Funding combines institutional support from hospitals and universities such as National University of Singapore, grant awards from bodies like Japan Society for the Promotion of Science, industry-sponsored trial budgets from multinational corporations, and public grants from agencies including National Natural Science Foundation of China and Ministry of Health, Labour and Welfare (Japan). Governance adheres to standards influenced by Declaration of Helsinki and regulatory requirements from agencies like Central Drugs Standard Control Organization (India) and Therapeutic Goods Administration (Australia), with oversight by data monitoring committees and legal frameworks negotiated with corporate partners including GlaxoSmithKline.

Impact and Notable Contributions

The consortium contributed to practice-changing evidence in areas such as targeted therapy through collaborations reminiscent of landmark studies from KEYNOTE-style programs, biomarker-driven approaches paralleling work at The Cancer Genome Atlas, and implementation science initiatives similar to those by CDC. Publications and guideline influences reflect collaboration with journals and societies such as The Lancet Oncology, Journal of Clinical Oncology, and The New England Journal of Medicine, and have informed national policies in countries including Japan, China, South Korea, and Singapore. Training programs and fellow exchanges with institutions like Harvard Medical School and University of Oxford have built investigator capacity, while multi-institutional datasets have supported pan-Asian analyses influencing drug approvals and clinical practice across the region.

Category:Medical research organizations